Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Current Assets (2023 - 2026)

Contineum Therapeutics' Current Assets history spans 4 years, with the latest figure at $253.0 million for Q1 2026.

  • Quarterly Current Assets rose 31.66% to $253.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $253.0 million through Mar 2026, up 31.66% year-over-year, with the annual reading at $267.9 million for FY2025, 29.81% up from the prior year.
  • Current Assets came in at $253.0 million for Q1 2026, down from $267.9 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $267.9 million in Q4 2025 to a low of $119.7 million in Q1 2024.
  • The 4-year median for Current Assets is $199.3 million (2024), against an average of $196.4 million.
  • Year-over-year, Current Assets soared 61.61% in 2024 and then fell 19.74% in 2025.
  • Contineum Therapeutics' Current Assets stood at $127.7 million in 2023, then skyrocketed by 61.61% to $206.4 million in 2024, then rose by 29.81% to $267.9 million in 2025, then dropped by 5.58% to $253.0 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Current Assets are $253.0 million (Q1 2026), $267.9 million (Q4 2025), and $184.9 million (Q3 2025).